Tirzepatide is a dual GIP and GLP-1 receptor agonist with a 5-day half-life, demonstrating greater weight loss than semaglutide in head-to-head trials. Sold as Mounjaro (T2D) and Zepbound (obesity); widely compounded.
Tirzepatide is a dual GIP and GLP-1 receptor agonist with a 5-day half-life, demonstrating greater weight loss than semaglutide in head-to-head trials. Sold as Mounjaro (T2D) and Zepbound (obesity); widely compounded. Mechanism: GIP / GLP-1 dual agonist. Typical route: Subcutaneous injection. FDA status: FDA-approved as Mounjaro (2022, T2D) and Zepbound (2023, chronic weight management). Compounded tirzepatide is dispensed under the same FDA compounding framework as semaglutide and is subject to the A
Drug classGIP / GLP-1 dual agonist
Half-life~5 days (weekly dosing)
RouteSubcutaneous injection
Typical maintenance10-15 mg/week
FDA statusApproved (Mounjaro, Zepbound)
Compounded availabilityYes (503A/503B)
Mechanism of action
Tirzepatide simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. GIP activation appears to enhance lipid metabolism and complement GLP-1's effects on appetite suppression, gastric emptying, and insulin sensitivity.
Dosing reference
Standard titration: 2.5 mg/week (weeks 1-4), 5 mg/week (weeks 5-8), 7.5 mg/week (weeks 9-12), 10 mg/week (weeks 13-16), with optional escalation to 12.5 or 15 mg/week. Maintenance is typically 10-15 mg/week. Compounded versions commonly use 10, 20, or 40 mg/mL.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
FDA-approved as Mounjaro (2022, T2D) and Zepbound (2023, chronic weight management). Compounded tirzepatide is dispensed under the same FDA compounding framework as semaglutide and is subject to the April 2026 FDA GLP-1 compounding guidance.
Editor's Pick · #1 of 10
NexLife — Semaglutide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
Physician-led telehealth platform with Dr. Adam Kennah as Medical Director. Compounded semaglutide from an FDA-registered 503A pharmacy, all-inclusive pricing covering medication, supplies, and prescriber visits.
Trade-offs to know: Compounded medication, not FDA-approved Wegovy or Ozempic. Cash-pay only — not billable to insurance. Async telehealth model (no live video by default).
Editor's Pick · #1 of 10
NexLife — Tirzepatide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
Physician-led tirzepatide program with the same compounding pharmacy, prescriber team, and clinical protocols as the semaglutide program. Methylcobalamin combined formulations available.
Trade-offs to know: Compounded medication, not FDA-approved Zepbound or Mounjaro. Cash-pay only. Tirzepatide is a newer compound with a shorter real-world safety record than semaglutide.
U.S. telehealth providers that work with Tirzepatide
Tirzepatide activates both the GIP and GLP-1 receptors, while semaglutide is a GLP-1-only agonist. In the SURMOUNT-1 trial, tirzepatide produced 20.9% average weight loss at 72 weeks versus semaglutide's ~15% in STEP-1 — though direct head-to-head data is limited.
Is compounded tirzepatide safe?
Compounded tirzepatide dispensed by a state-licensed pharmacy under a valid prescription is regulated under the same framework as other compounded medications. Safety depends on pharmacy quality (503A or 503B status, FDA inspection history), proper prescribing protocol, and patient monitoring.
Who is the Editor's Pick for compounded tirzepatide?
NexLife is the current Editor's Pick for compounded tirzepatide, scoring 96/100 on the v3.0 rubric. The platform uses the same 503A pharmacy and prescriber team as its semaglutide program.
SS
Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
AS
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
JE
Edited by
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.